Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Gilead Sciences IncGILD983.273.966.1012.580.56%3.00%75.62$89.67-$9,401.99170,547$89.89

Detail of Gilead Sciences Inc

 
CEO
Mr. Daniel P. O'Day
Employees
18000
Industry
Drug Manufacturers - General
Sector
Healthcare
Market cap
$112B

Company details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$28.30B
Cost of goods (CoG)
-$6.76B
Gross profit (GP)
$21.54B
Operating expense (OE)
-$13.90B
Research and development (R&D)
-$8.10B
General and administrative (G&A)
-$5.79B
Operating income (OI)
$7.64B
Other income expense (OIE)
-$6.54B
Pretax income (PI)
$176.00M
Tax (TAX)
-$63.00M
Net income (NI)
$114.00M
Gilead Sciences Inc
GILD • XNGS • US
$89.89
+3.89 (4.52%)
Stock vs Industry average
  • Industry average

Dividend yield
3.43%
Trailing annual dividend rate
$3.06
Payout ratio
3,400.00%
EPS
$0.09
Margin profit
0.44%
52 week low
$63.150002
52 week high
$98.514999
50-day simple moving average
$90.32
200-day simple moving average
$89.67
Percent held by insiders
0.12%
Percent held by institutions
88.39%
Dividend yield
3.36%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
GILD +4.52%
eps change
GILD -42.86%